White blood cells (leukocytes), which are a subset of cytokines (secreted proteins and signaling molecules), were the first to be observed to express interleukins. Interleukins are crucial for the immune system's proper operation, and there have been rare cases of their deficiency that have all been associated with autoimmune disorders or immune deficiencies. Helper CD4 T lymphocytes, along with monocytes, macrophages, and endothelial cells, produce the majority of interleukins. They support the growth and differentiation of hematopoietic cells, including T and B lymphocytes. The development of spatial memories in mice has also been linked to interleukin receptors on astrocytes in the hippocampus.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74950 | Basiliximab (CHI 621) | 179045-86-4 | Basiliximab (CHI 621) is a recombinant chimeric mouse/human IgG1 monoclonal anti-interleukin-2 receptor antibody. |
|
V74956 | Bermekimab (MABp1) | 1401965-15-8 | Bermekimab (MABp1) is a human monoclonal antibody (mAb) targeting interleukin-1alpa (IL-1α). |
|
V74937 | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) | 1418205-77-2 | Bimekizumab (Bimzelx; Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanized monoclonal antibody (mAb) that selectively neutralizes IL-17A and IL-17F. |
|
V67806 | BMS-986251 | 2460133-35-9 | BMS-986251 is an orally bioactive, selective RORγt inverse agonist/activator with EC50 of 12 nM for RORγt GAL4. |
|
V74997 | Brazikumab (AMG 139; MEDI2070) | 1610353-18-8 | Brazikumab (AMG 139) is a human IgG2 monoclonal antibody (mAb) that selectively binds to the p19 subunit of IL-23 with a Kd of 0.138 nM for human IL-23. |
|
V74958 | Briakinumab (ABT-874) | 339308-60-0 | Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody (mAb). |
|
V74949 | Brodalumab (AMG 827; KHK4827) | 1174395-19-7 | Brodalumab (AMG 827) is an anti-human interleukin 17 receptor (IL-17R) IgG2 monoclonal antibody (mAb) indicated for the study of moderate to severe plaque psoriasis and rheumatoid arthritis. |
|
V74983 | Camidanlumab (HuMax-TAC) | 921618-45-3 | Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody (mAb). |
|
V74969 | Camoteskimab (AVTX-007; CERC-007; MEDI 2338) | 2492472-82-7 | Camoteskimab (AVTX-007) is a fully human, high-affinity anti-IL-18 monoclonal antibody (mAb). |
|
V74935 | Canakinumab (Ilaris; ACZ 885) | 914613-48-2 | Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody (mAb). |
|
V75051 | Casdozokitug (SRF-388) | 2643331-37-5 | Casdozokitug (SRF-388) is an IgG1κ antibody targeting IL27. |
|
V74942 | CC-90002 | 2085844-54-6 | CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). |
|
V75003 | Cendakimab (Cendakimab; RPC 4046; ABT 308; CC-93538) | 2151032-62-9 | Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized recombinant monoclonal antibody (mAb) against IL-13. |
|
V74972 | Cergutuzumab amunaleukin (CEA-IL2v; RG 7813; RO 6895882) | 1509916-03-3 | Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine based on carcinoembryonic antigen (CEA) targeting IL-2 variants. |
|
V78806 | Citrullinated LL-37 2cit | Citrullinated LL-37 2cit is a citrullinated LL-37 peptide. | |
|
V75034 | CTX-471 | 2377152-49-1 | CTX-471 is a fully human monoclonal antibody (mAb) against CD137. |
|
V75041 | Dectrekumab (Detrekumab; QAX576) | 1528523-94-5 | Dectrekumab (QAX576) is a humanized monoclonal antibody (mAb) targeting IL-13. |
|
V75004 | Depemokimab (GSK-3511294) | 2243274-14-6 | Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody (mAb). |
|
V75029 | Diacerein-d6 (Diacerhein-d6; Diacetylrhein-d6) | 1325559-27-0 | Diacerein-d6 is the deuterium labelled form of Diacerein. |
|
V75030 | Dovanvetmab (ZTS-00521505) | 2171034-71-0 | Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
